A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Part of paid clinical trials in Los Alamitos, California.

Sponsor
GlaxoSmithKline
Study ID
NCT06885034
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastrointestinal Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GSK5764227 — BIOLOGICAL
    GSK5764227 will be administered

Study Details

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Key Dates

Start date
Jun 11, 2025
Status verified
Nov 2025
Primary completion
Nov 11, 2027
Completion
Jun 23, 2028

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CRC-A: GSK5764227 (Dose 1)
  • Experimental: CRC-A: GSK5764227 (Dose 2)
  • Experimental: CRC-B: GSK5764227 (Dose 3)
  • Experimental: CRC-B: GSK5764227 (Dose 4)
  • Experimental: PDAC: GSK5764227 (Dose 5)

Primary Outcome Measure

Confirmed Objective Response Rate (ORR) [ Time Frame: Up to approximately 22 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteLos AlamitosCalifornia90720
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Vu Phan (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteWhittierCalifornia90602
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Andrew Pham (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteNew YorkNew York10065
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Andrea Cercek (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteDurhamNorth Carolina27710
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Nicholas DeVito (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteHoustonTexas77479
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Kanwal Raghav (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteSan AntonioTexas78229
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Drew W Rasco (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteWenatcheeWashington98801
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Lindsay Overton (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Alamitos, CA

By research site
GSK Investigational Site· Los Alamitos, CAGSK Investigational Site· Whittier, CAGSK Investigational Site· New York, NYGSK Investigational Site· Durham, NCGSK Investigational Site· Houston, TXGSK Investigational Site· San Antonio, TX

Related Studies